Cynosure Group LLC Sells 174 Shares of Transcat, Inc. (NASDAQ:TRNS)

Cynosure Group LLC decreased its holdings in shares of Transcat, Inc. (NASDAQ:TRNS) by 3.1% in the fourth quarter, HoldingsChannel reports. The firm owned 5,486 shares of the scientific and technical instruments company’s stock after selling 174 shares during the quarter. Cynosure Group LLC’s holdings in Transcat were worth $580,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Geode Capital Management LLC raised its holdings in shares of Transcat by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 219,354 shares of the scientific and technical instruments company’s stock valued at $23,200,000 after acquiring an additional 1,881 shares in the last quarter. JPMorgan Chase & Co. increased its position in Transcat by 153.1% during the 4th quarter. JPMorgan Chase & Co. now owns 26,434 shares of the scientific and technical instruments company’s stock valued at $2,795,000 after purchasing an additional 15,991 shares during the period. KLP Kapitalforvaltning AS bought a new position in Transcat in the 4th quarter worth $190,000. Diamond Hill Capital Management Inc. lifted its position in shares of Transcat by 11.7% in the 4th quarter. Diamond Hill Capital Management Inc. now owns 6,143 shares of the scientific and technical instruments company’s stock worth $650,000 after purchasing an additional 643 shares during the period. Finally, Raymond James Financial Inc. bought a new stake in shares of Transcat during the 4th quarter valued at about $2,071,000. Hedge funds and other institutional investors own 98.34% of the company’s stock.

Wall Street Analyst Weigh In

TRNS has been the subject of a number of research reports. Northland Securities reissued a “market perform” rating and issued a $85.00 price target (down from $110.00) on shares of Transcat in a research note on Wednesday, January 29th. HC Wainwright lowered their target price on Transcat from $126.00 to $106.00 and set a “buy” rating for the company in a research note on Wednesday, January 29th. StockNews.com cut Transcat from a “hold” rating to a “sell” rating in a research note on Wednesday, February 5th. Oppenheimer lowered Transcat from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 29th. Finally, Craig Hallum boosted their target price on shares of Transcat from $113.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, December 12th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, Transcat has a consensus rating of “Hold” and a consensus target price of $111.50.

Transcat Stock Performance

Shares of Transcat stock opened at $74.16 on Wednesday. The firm’s 50-day moving average is $78.71 and its 200 day moving average is $100.04. The stock has a market cap of $690.36 million, a price-to-earnings ratio of 40.09 and a beta of 0.66. Transcat, Inc. has a 1 year low of $67.56 and a 1 year high of $147.12. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.42 and a quick ratio of 1.98.

Transcat (NASDAQ:TRNS) last released its quarterly earnings data on Monday, January 27th. The scientific and technical instruments company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.38 by $0.07. Transcat had a return on equity of 7.23% and a net margin of 6.22%. During the same period in the prior year, the business posted $0.56 earnings per share. Sell-side analysts anticipate that Transcat, Inc. will post 2.3 EPS for the current fiscal year.

Insider Buying and Selling at Transcat

In other Transcat news, Director Craig D. Cairns acquired 1,200 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was purchased at an average price of $77.02 per share, with a total value of $92,424.00. Following the transaction, the director now directly owns 1,910 shares in the company, valued at approximately $147,108.20. The trade was a 169.01 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 2.30% of the stock is owned by corporate insiders.

Transcat Company Profile

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.